Poster | 2022 ISLB Annual Congress | Collaborative Meta-analytical Approaches to Advance the Use of ctDNA in Clinical Cancer Research: The Friends of Cancer Research ctMoniTR Project
2023 Scientific Report
Poster | 2023 ASCO Annual Meeting | Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials
2022 Scientific Report
Peer Review | Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in monitoring response to ICI, but uncertainty exists in the generalizability of these studies. Here, the role of ctDNA for monitoring response to ICI is assessed…